TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at ACTRIMS
Tweet Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
